Figure 1From: Surgical treatment for locally advanced lower third rectal cancer after neoadjuvent chemoradiation with capecitabine: prospective phase II trialThe two year overall survival. NB. After a median follow up of 25 months, the 2 year survival was 79%.Back to article page